Please note that some translations using Google Translate may not be accurately represented, and image captions and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result for using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
The Bing Center for Waldenström's Macroglobulinemia encompasses a large, international team of laboratory-based and clinical investigators who are striving to find more effective therapies for Waldenström's macroglobulinemia and, someday, a cure.
Steven P. Treon, MD, PhD, director, Bing Center for Waldenström's Macroglobulinemia
Treon's main research interests focus on understanding the genetic basis and pathogenesis of Waldenström's and the development of novel therapeutics. He serves on the editorial boards of Journal of Clinical Oncology,
Blood, Clinical Cancer Research, and The Lancet. He has been honored with several research and academic awards, including the Robert A. Kyle Award for Waldenström's.
Jorge J. Castillo, MD
Castillo's research studies the various risk factors that could be associated with an increased risk of developing hematologic malignancies. He has run a series of investigator-initiated prospective clinical trials using
non-chemotherapeutic regimens, and has developed several multi-institutional efforts to study Waldenström's macroglobulinemia and other lymphomas. His work has been published in Journal of Clinical Oncology, Blood, Leukemia,
Cancer, British Journal of Haematology, and Leukemia and Lymphoma.
Toni Dubeau, NP
Dubeau joined the Waldenström's team to foster long-term relationships with patients in this setting. Before her work at Dana-Farber, she spent 13 years at Brigham and Women's Hospital caring for patients in a variety
of settings, including bone marrow transplant and cardiology.
Appointments and Second Opinions